Products
Data
Feature
Plans
Request Demo
Sign Up for Free
Blog
Valuable Targets
Advanced Tech.
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
6 min read
Aadi Subsidiary, Inc. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
4 August 2026
Aadi Subsidiary, Inc. 2026 BD opportunity scan covering pipeline assets, ownership, stage, transaction precedents, financial signals, IP risk and outreach priorities.
Read →
Latest Hotspot
7 min read
Adaptive Phage Therapeutics, Inc. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
4 August 2026
Adaptive Phage Therapeutics, Inc. 2026 BD opportunity scan covering pipeline assets, ownership, stage, transaction precedents, financial signals, IP risk and outreach priorities.
Read →
Latest Hotspot
8 min read
A.Menarini Industrie Farmaceutiche Riunite Srl Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
4 August 2026
A.Menarini Industrie Farmaceutiche Riunite Srl 2026 BD opportunity scan covering pipeline assets, ownership, stage, transaction precedents, financial signals, IP risk and outreach priorities.
Read →
Latest Hotspot
7 min read
Adalvo Ltd. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
4 August 2026
Adalvo Ltd. 2026 BD opportunity scan covering pipeline assets, ownership, stage, transaction precedents, financial signals, IP risk and outreach priorities.
Read →
Latest Hotspot
8 min read
Zhaoke Ophthalmology Ltd. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
4 August 2026
Zhaoke Ophthalmology Ltd. 2026 BD opportunity scan covering pipeline assets, ownership, stage, transaction precedents, financial signals, IP risk and outreach priorities.
Read →
Latest Hotspot
8 min read
Yoltech Therapeutics Co., Ltd. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
4 August 2026
Yoltech Therapeutics Co., Ltd. 2026 BD opportunity scan covering pipeline assets, ownership, stage, transaction precedents, financial signals, IP risk and outreach priorities.
Read →
Latest Hotspot
7 min read
2seventy Bio, Inc. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
4 August 2026
2seventy Bio, Inc. 2026 BD opportunity scan covering pipeline assets, ownership, stage, transaction precedents, financial signals, IP risk and outreach priorities.
Read →
Latest Hotspot
8 min read
Virogin Biotech Ltd. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
4 August 2026
Virogin Biotech Ltd. 2026 BD opportunity scan covering pipeline assets, ownership, stage, transaction precedents, financial signals, IP risk and outreach priorities.
Read →
Latest Hotspot
7 min read
Siolta Therapeutics, Inc. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
4 August 2026
Siolta Therapeutics, Inc. 2026 BD opportunity scan covering pipeline assets, ownership, stage, transaction precedents, financial signals, IP risk and outreach priorities.
Read →
Latest Hotspot
8 min read
Theriva Biologics, Inc. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
4 August 2026
Theriva Biologics, Inc. 2026 BD opportunity scan covering pipeline assets, ownership, stage, transaction precedents, financial signals, IP risk and outreach priorities.
Read →
Latest Hotspot
8 min read
TCR² Therapeutics, Inc. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
4 August 2026
TCR² Therapeutics, Inc. 2026 BD opportunity scan covering pipeline assets, ownership, stage, transaction precedents, financial signals, IP risk and outreach priorities.
Read →
Latest Hotspot
8 min read
Transgene SA Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
4 August 2026
Transgene SA 2026 BD opportunity scan covering pipeline assets, ownership, stage, transaction precedents, financial signals, IP risk and outreach priorities.
Read →
<
1
<<
1652
1653
1654
1655
1656
>>
2926
>